open access

Vol 29, No 1 (2022)
Letter to the Editor
Submitted: 2021-08-14
Accepted: 2021-08-20
Published online: 2021-10-08
Get Citation

Variant lambda of the severe acute respiratory syndrome coronavirus 2: A serious threat or the beginning of further dangerous mutations

Lukasz Szarpak123, Ivan Savytskyi4, Michal Pruc35, Anatolyi Gozhenko4, Krzysztof J. Filipiak1, Zubaid Rafique6, Frank W. Peacock6, Olayinka S. Ilesanmi78, Francesco Chirico910
DOI: 10.5603/CJ.a2021.0121
·
Pubmed: 34642924
·
Cardiol J 2022;29(1):176-177.
Affiliations
  1. Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
  2. Research Unit, Maria Sklodowska-Curie Bialystok Oncology Center, Bialystok, Poland
  3. Polish Society of Disaster Medicine, Warsaw, Poland
  4. International European University, Kiev, Ukraine
  5. Institute of Outcomes Research, Polonia University, Warsaw, Poland
  6. Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States
  7. Department of Community Medicine, College of Medicine, University of Ibadan, Oyo State, Nigeria
  8. Department of Community Medicine, University College Hospital, Ibadan, Oyo State, Nigeria
  9. Post-graduate School of Occupational Health, Università Cattolica del Sacro Cuore, Rome, Italy
  10. Health Service Department, Italian State Police, Milan, Italy

open access

Vol 29, No 1 (2022)
Letters to the Editor — COVID-19
Submitted: 2021-08-14
Accepted: 2021-08-20
Published online: 2021-10-08

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Variant lambda of the severe acute respiratory syndrome coronavirus 2: A serious threat or the beginning of further dangerous mutations

Journal

Cardiology Journal

Issue

Vol 29, No 1 (2022)

Article type

Letter to the Editor

Pages

176-177

Published online

2021-10-08

Page views

3075

Article views/downloads

548

DOI

10.5603/CJ.a2021.0121

Pubmed

34642924

Bibliographic record

Cardiol J 2022;29(1):176-177.

Authors

Lukasz Szarpak
Ivan Savytskyi
Michal Pruc
Anatolyi Gozhenko
Krzysztof J. Filipiak
Zubaid Rafique
Frank W. Peacock
Olayinka S. Ilesanmi
Francesco Chirico

References (6)
  1. "Tracking SARS-CoV-2 variants". who.int. World Health Organization. Updated frequently. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (Access: 2 Aug 2021).
  2. Wink PL, Volpato FC, Monteiro FL, et al. First identification of SARS-CoV-2 Lambda (C.37) variant in Southern Brazil. Infect Control Hosp Epidemiol. 2021 [Epub ahead of print]: 1–7.
  3. Kimura I, Kosugi Y, Wu J, et al. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv. 2021; 2021.07.28.454085.
  4. Acevedo M, Alonso-Palomares L, Bustamante A, et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv. 2021; 2021.06.28.21259673.
  5. Tada T, Zhou H, Dcosta B, et al. SARS-CoV-2 Lambda Variant Remains Susceptible to Neutralization by mRNA Vaccine-elicited Antibodies and Convalescent Serum. bioRxiv. 2021; 2021.07.02.450959.
  6. Weekly epidemiological update on COVID-19 - 15 June 2021 Edition 44 15 June 2021 | Emergency Situational Update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---15-june-2021 (Access: 2 August 2021).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl